Cetrotide (cetrorelix) / EMD Serono 
Welcome,         Profile    Billing    Logout  
 39 Diseases   32 Trials   32 Trials   385 News 


«123456»
  • ||||||||||  Ozarelix (D-63153) / Spectrum Pharma, Firmagon (degarelix) / Astellas, Ferring, Cetrotide (cetrorelix) / EMD Serono
    Journal:  Aggregation Behavior of Structurally Similar Therapeutic Peptides Investigated by H NMR and All-Atom Molecular Dynamics Simulations. (Pubmed Central) -  Apr 12, 2022   
    The AA-MD simulations also provided molecular-level insights into aggregation dynamics, aggregation pathways, and the influence of different structural elements on peptide aggregation propensity and intermolecular interactions within the aggregates. Taken together, the findings from this study illustrate that H NMR and AA-MD simulations can be useful, complementary tools in early evaluation of aggregation propensity and formulation development for peptide drugs.
  • ||||||||||  Firmagon (degarelix) / Astellas, Ferring, Cetrotide (cetrorelix) / EMD Serono
    Trial completion date, Trial primary completion date:  Dysregulation of FSH in Obesity: Functional and Statistical Analysis (clinicaltrials.gov) -  Apr 7, 2022   
    P=N/A,  N=99, Completed, 
    Taken together, the findings from this study illustrate that H NMR and AA-MD simulations can be useful, complementary tools in early evaluation of aggregation propensity and formulation development for peptide drugs. Trial completion date: Mar 2021 --> Jun 2021 | Trial primary completion date: Mar 2021 --> Jun 2021
  • ||||||||||  Cetrotide (cetrorelix) / EMD Serono
    Preclinical, Journal:  Bioluminescent imaging in induced mouse models of endometriosis reveals differences in four model variations. (Pubmed Central) -  Apr 1, 2022   
    We compared longitudinal bioluminescence and histology of lesions, sensory behaviour of mice with induced endometriosis and the impact of the gonadotropin-releasing hormone antagonist Cetrorelix on lesion regression and sensory behaviour...Collectively, our results demonstrate key differences in the progression of the 'disease' across different mouse models of endometriosis. We propose that validation and testing in multiple models, each of which may be representative of the different subtypes / heterogeneity observed in women should become a standard approach to discovery science in the field of endometriosis.
  • ||||||||||  Utrogestan (progesterone) / Besins Healthcare
    Trial completion date, Trial primary completion date:  Prog_STIM: Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles. (clinicaltrials.gov) -  Mar 31, 2022   
    P=N/A,  N=44, Recruiting, 
    We propose that validation and testing in multiple models, each of which may be representative of the different subtypes / heterogeneity observed in women should become a standard approach to discovery science in the field of endometriosis. Trial completion date: Jan 2022 --> Jan 2023 | Trial primary completion date: Sep 2021 --> Sep 2022
  • ||||||||||  letrozole / Generic mfg.
    Trial completion date, Trial primary completion date:  Letrozole in Stimulated IVF Cycles (clinicaltrials.gov) -  Mar 31, 2022   
    P3,  N=900, Recruiting, 
    Trial completion date: Jan 2022 --> Jan 2023 | Trial primary completion date: Sep 2021 --> Sep 2022 Trial completion date: Dec 2022 --> Oct 2023 | Trial primary completion date: Dec 2021 --> Apr 2022
  • ||||||||||  Rekovelle (follitropin delta) / Ferring
    Trial completion, Trial completion date:  Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND) (clinicaltrials.gov) -  Feb 23, 2022   
    P3,  N=437, Completed, 
    Clinical studies are on the way to test this hypothesis. Active, not recruiting --> Completed | Trial completion date: Sep 2022 --> Feb 2022
  • ||||||||||  Cetrotide (cetrorelix) / EMD Serono
    Clinical, Journal:  GnRH Antagonist Protocol With Cessation of Cetrorelix on Trigger Day Improves Embryological Outcomes for Patients With Sufficient Ovarian Reserve. (Pubmed Central) -  Feb 19, 2022   
    Furthermore, for patients with 1.1 ≤ AMH ≤ 4.7 ng/ml, all embryological outcomes were significantly higher in Group B compared with Group A. For patients with AMH > 4.7 ng/ml, the number of oocytes retrieved, fertilization rate (2PN) of IVF cycles and proportion of day 3 good quality embryos were all significantly higher in Group B. For patients with age 35 years or AMH < 1.1 ng/ml. GnRH-ant protocol with cessation of cetrorelix on trigger day improved embryological outcomes for young patients or patients with sufficient ovarian reserve, and was effective at preventing preovulation.
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders (clinicaltrials.gov) -  Feb 17, 2022   
    P3,  N=90, Completed, 
    Eventually, the proposed method was used for the extraction and quantification of target therapeutic peptides in plasma and urine samples, and satisfactory relative recoveries were achieved in the range of 90.6-110.3%. Not yet recruiting --> Completed | Trial completion date: Dec 2021 --> Sep 2021 | Trial primary completion date: Sep 2021 --> Mar 2021
  • ||||||||||  Cetrotide (cetrorelix) / EMD Serono
    Clinical, Journal:  Pregnancy outcomes following different protocols of controlled ovarian hyperstimulation in couples undergoing intrauterine insemination. (Pubmed Central) -  Jan 13, 2022   
    Our observations show that increased numbers of preovulatory follicles or endometrium thickness do not necessarily improve pregnancy outcomes, as pregnancy outcomes are also subjected to the type of COH utilized agent. In this regard, letrozole produced fewer preovulatory follicles, and did not significantly increase endometrium thickness, but significantly improved pregnancy outcomes in comparison to CC and cetrorelix acetate.
  • ||||||||||  Cetrotide (cetrorelix) / EMD Serono
    Journal:  Neuromodulatory effects of GnRH on the caudal neurosecretory Dahlgren cells in female olive flounder. (Pubmed Central) -  Nov 29, 2021   
    A positive correlation was observed between the UII and GnRH-R mRNA levels in CNSS or gonadosomatic index (GSI) during the breeding season. These findings are the first demonstration of the ability of GnRH acts as a modulator within the CNSS and add to our understanding of the physiological role of the CNSS in reproduction and seasonal adaptation.
  • ||||||||||  Cetrotide (cetrorelix) / EMD Serono
    Preclinical, Journal:  Neuromodulatory effect of GnRH from coeliac ganglion on luteal regression in the late pregnant rat. (Pubmed Central) -  Nov 29, 2021   
    Cetrorelix (CTX), a GnRH receptor antagonist, was added into the ganglionic compartment while the control systems were untreated...In turn, CTX in CG caused an increase in ovarian progesterone release...CTX in CG decreased the ovarian noradrenaline release. The present study provides evidence that GnRH from CG may trigger neuronal signals that promote the luteal regression in late pregnancy by affecting the release of NO and noradrenaline in the ovary.
  • ||||||||||  Cetrotide (cetrorelix) / EMD Serono
    Clinical, Journal:  Ovarian Filariasis: Diagnosis by detection of microfilariae in follicular fluid, a case report. (Pubmed Central) -  Nov 25, 2021   
    Antagonist protocol is one of the standard protocols used for controlled ovarian hyperstimulation as a part of the IVF/ICSI(in-vitro fertilization / intracytoplasmic sperm injection) procedure where GnRH antagonist (cetrorelix) is used to suppress the endogenous LH surge...The patient was treated with Diethylcarbamazine citrate. There are so many reports about scrotal Filariasis, but rare literature quotes ovarian Filariasis.
  • ||||||||||  Cetrotide (cetrorelix) / EMD Serono
    Trial completion date, Trial primary completion date:  The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol (clinicaltrials.gov) -  Nov 18, 2021   
    P=N/A,  N=142, Recruiting, 
    There are so many reports about scrotal Filariasis, but rare literature quotes ovarian Filariasis. Trial completion date: Mar 2022 --> Jun 2022 | Trial primary completion date: Jul 2021 --> Jun 2022
  • ||||||||||  Rekovelle (follitropin delta) / Ferring
    Enrollment closed:  Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND) (clinicaltrials.gov) -  Nov 16, 2021   
    P3,  N=437, Active, not recruiting, 
    Trial completion date: Mar 2022 --> Jun 2022 | Trial primary completion date: Jul 2021 --> Jun 2022 Recruiting --> Active, not recruiting
  • ||||||||||  Cetrotide (cetrorelix) / EMD Serono
    Journal:  Kisspeptin induces LH release and ovulation in an induced ovulator. (Pubmed Central) -  Sep 12, 2021   
    Llamas pretreated with saline had elevated plasma LH concentrations and ovulated (6/6) whereas llamas pretreated with cetrorelix did not (0/6)...We found no colocalization between kisspeptin and NGF receptors by double immunofluorescence. Functional and morphological findings support the concept that kisspeptin is a mediator of the LH secretory pathway in llamas; however, the role of kisspeptins in the NGF ovulation-inducing pathway in camelids remains unclear since NGF receptors were not detected in kisspeptin neurons in the hypothalamus.
  • ||||||||||  Cetrotide (cetrorelix) / EMD Serono
    Preclinical, Journal:  Effect of Cetrorelix administration on ovarian stimulation in aged mice. (Pubmed Central) -  Jul 28, 2021   
    It is concluded that Cetrorelix improved the effect of superovulation in aged mice without reducing oocyte quality. This procedure will contribute to animal welfare by extending the effective utilization of aged female breeding mice.
  • ||||||||||  Cetrotide (cetrorelix) / EMD Serono
    New trial:  Acupuncture in the Freeze-all IVF Cycle (clinicaltrials.gov) -  Jun 18, 2021   
    P=N/A,  N=90, Not yet recruiting, 
  • ||||||||||  Cetrotide (cetrorelix) / EMD Serono
    Clinical, Review, Journal:  Controlled ovarian stimulation therapy as a potential risk for the development and progression of renal cell carcinomas: A case report and literature review. (Pubmed Central) -  Jun 8, 2021   
    A 35-year-old woman received fertility stimulation treatment with follitropin alfa 900 units, human chorionic gonadotropic hormone 5,000 units, injectable leuprolide 1 mg/0.2 ml and cetrotide 0.25 mg...To the best of our knowledge, this was the first time that a case of ovarian stimulation therapy was associated with the development of RCC. This case raises concerns about the potential oncogenic effect of controlled ovarian stimulation therapy in RCC promotion, suggesting a need for systematic research to clarify the clinical significance of existing pre-clinical data.
  • ||||||||||  Cetrotide (cetrorelix) / EMD Serono
    Trial completion, Preclinical:  NATOS: NATural Ovarian Stimulation (clinicaltrials.gov) -  Apr 30, 2021   
    P4,  N=129, Completed, 
    This case raises concerns about the potential oncogenic effect of controlled ovarian stimulation therapy in RCC promotion, suggesting a need for systematic research to clarify the clinical significance of existing pre-clinical data. Active, not recruiting --> Completed
  • ||||||||||  letrozole / Generic mfg.
    Trial completion date, Trial primary completion date:  Letrozole in Stimulated IVF Cycles (clinicaltrials.gov) -  Apr 29, 2021   
    P3,  N=900, Recruiting, 
    Active, not recruiting --> Completed Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2021
  • ||||||||||  Cetrotide (cetrorelix) / EMD Serono
    Journal:  Gonadotropin-releasing hormone-independent effects of recombinant vertebrate ancient long opsin in the goldfish Carassius auratus reveal alternative reproduction pathways. (Pubmed Central) -  Apr 13, 2021   
    Goldfish were injected with recombinant VAL-opsin protein (0.5 μg/g body mass) and/or the GnRH antagonist cetrorelix (0.5 μg/fish), and changes in the mRNA expression levels of genes associated with goldfish reproduction were measured by quantitative polymerase chain reaction, including those involved in the hypothalamus-pituitary-gonad (HPG) axis, VAL-opsin, GnRH, the gonadotropins (GTHs) luteinizing hormone and follicle-stimulating hormone, and estrogen receptor (ER)...These results indicate that green LED is an effective light source to promote the expression of sex hormones in fish. Moreover, VAL-opsin not only affects activity of the HPG axis but also appears to act on the pituitary gland directly to stimulate a new sexual maturation pathway that promotes the secretion of GTHs independent of GnRH.
  • ||||||||||  Orgalutran (ganirelix acetate) / Organon, Cetrotide (cetrorelix) / EMD Serono
    Trial completion date, Trial primary completion date:  Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response (clinicaltrials.gov) -  Mar 18, 2021   
    P3,  N=784, Recruiting, 
    Influence of various deposition parameters was studied to obtain the optimized conditions for the growth of a thin film based EO modulator.Surface morphology of the SBN60 and SBN75 thin film after deposition using PLD technique Trial completion date: Oct 2022 --> Oct 2024 | Trial primary completion date: Jul 2022 --> Jul 2023